dcsimg

Improved erectile function1

CIALIS for use as needed improved Sexual Encounter Profile,
question 3 (SEP 3)* values in patients with ED

Retrospective analysis of 11 integrated, randomized, double-blind, placebo-controlled trials of 2102 patients stratified by baseline severity (mild, moderate, severe) receiving placebo (n=638), CIALIS 10 mg (n=321), or CIALIS 20 mg (n=1143). Per protocol, patients with "mild" or "mild-moderate" ED were combined into a single category of "mild" ED.

  • Works fast—in as little as 16 minutes in 32% of men taking CIALIS 20 mg vs 15% taking placebo2,3†
  • Efficacy for up to 36 hours4‡§
  • Mean SEP 3 scores in all patients5
    • Endpoint: placebo 31%, CIALIS 10 mg 58%, CIALIS 20 mg 68%
    • Change from baseline: placebo 8%, CIALIS 10 mg 34%, CIALIS 20 mg 46%

*Sexual Encounter Profile, question 3 (SEP 3) is a yes/no question: "Did your erection last long enough for you to have successful intercourse?"

Individual results may vary. 30-minute onset in 52% of men taking CIALIS 20 mg (n=75) vs 35% taking placebo (n=74); P<.05. Onset defined as the earliest time to a successful erection (at least 1 erection in 4 attempts that led to successful intercourse).2,4

Individual results may vary. Not studied for multiple attempts per dose.

§In 2 studies, men were instructed to attempt intercourse at 24 or 36 hours after taking a single dose of CIALIS. CIALIS was shown to improve, compared to placebo, the ability of men with ED to have a single successful intercourse attempt at each of these time points.

CIALIS for use as needed provided improvement in erectile function for men
with ED and controlled hypertension or cardiovascular disease (CVD)1

Select Important Safety Information Related to Cardiovascular Considerations

  • Physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Treatments for erectile dysfunction (ED), including CIALIS, should not be used in men for whom sexual activity is inadvisable as a result of their underlying cardiovascular status. Patients who experience symptoms upon initiation of sexual activity should be advised to refrain from further sexual activity and seek immediate medical attention.
  • CIALIS was not studied in and is not recommended for the following groups of patients: those with myocardial infarction within the last 90 days; unstable angina or angina during sexual intercourse; stroke or heart failure within the last 6 months; uncontrolled arrhythmia; hypotension; uncontrolled hypertension; and hereditary degenerative retinal disorders.
  • Use of CIALIS with alpha-blockers, antihypertensives, or substantial amount of alcohol (≥5 units) may lead to hypotension.

Improved erection confidence6

CIALIS for use as needed improved International Index
of Erectile Function question 15 (IIEF 15) scores in ED patients

Results from a retrospective analysis of 17 placebo-controlled studies in the general ED population with a range of ED severity based on responses to the IIEF questionnaire.

  • Patient response to IIEF 15: "How do you rate your confidence that you could get and keep an erection?" Percentage based on total cohort population (placebo, N=1002; CIALIS 10 mg, N=527; CIALIS 20 mg, N=1816) as denominator
  • Mean IIEF 15 scores at baseline and endpoint: placebo, 1.94 and 2.24; CIALIS 10 mg, 1.90 and 3.05; CIALIS 20 mg, 1.98 and 3.44
CIALIS is the most prescribed oral ED treatment by urologists7

Information is based on IMS Total Rx data from April 2010 through March 2013.

Treatment-emergent adverse reactions4

Treatment-emergent adverse reactions reported by ≥2% of patients treated with CIALIS for use as needed (10 mg or 20 mg) and more frequent on drug than placebo in 8 primary, placebo-controlled, phase 3 studies (including a study in patients with diabetes).

  • Overall discontinuation rates in clinical trials were 3.1% for CIALIS 10 mg and 20 mg vs 1.4% for placebo

You are now leaving the
CialisMD.com Web site


The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC, does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC, is not responsible for the privacy policy of any third-party Web sites. We encourage you to read the privacy policy of every Web site you visit.

Continue Return